Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

A total of 20,146 patients with nephrolithiasis and type 2 diabetes, including those with gout at baseline, initiated an SGLT ...

There is also a strong rationale provided to avoid use of sliding-scale insulin and to consider the use of oral agents and ...

Use of sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs to treat type 2 diabetes may also help to lower the risk of ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

LifeVantage (LFVN) announced results from a human clinical trial performed on the new MindBody GLP-1 System. Results from the trial included a ...

The Director of Public Prosecutions (DPP) has officially withdrawn all charges against former Mungiki leader Maina Njenga. The announcement was made by Njenga’s lawyer Ndegwa Njiru on Monday, November ...

The Democratic Party for the People remains the third-largest opposition party in Japan, but its sharp gains in the Lower ...

She gives us each a simple form to fill out while she outlines the rules, saying visitors must always be accompanied and ...

Background The prosecution accuses Molly Katanga of killing her husband, an act allegedly carried out with malice ...